Bristol-Myers Squibb Co. [NYSE: BMY] price surged by 0.34 percent to reach at $0.15. The one-year BMY stock forecast points to a potential upside of 16.34. The average equity rating for BMY stock is currently 2.64, trading closer to a bullish pattern in the stock
Bristol-Myers Squibb Co. [NYSE: BMY] stock went on an upward path that rose over 1.30% on Friday, amounting to a one-week price increase of more than 1.35%. Over the last 12 months, BMY stock dropped by -29.96%. The one-year Bristol-Myers Squibb Co. stock forecast points
Bristol-Myers Squibb Co. [NYSE: BMY] closed the trading session at $48.28. The stocks have a year to date performance of -5.91 percent and weekly performance of -5.92 percent. The stock has been moved at -14.77 percent over the last six months. The stock has performed
Bristol-Myers Squibb Co. [NYSE: BMY] closed the trading session at $51.32. The company report on April 6, 2024 at 1:15 PM that Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the
Bristol-Myers Squibb Co. [NYSE: BMY] traded at a high on Thursday, posting a 1.84 gain after which it closed the day’ session at $54.23. The company report on March 29, 2024 at 9:45 AM that Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve
Bristol-Myers Squibb Co. [NYSE: BMY] gained 0.62% on the last trading session, reaching $52.25 price per share at the time. The company report on March 25, 2024 at 8:00 AM that Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific
Bristol-Myers Squibb Co. [NYSE: BMY] surged by $0.34 during the normal trading session on while it closed the day at $51.93. The company report on March 20, 2024 at 4:45 PM that Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved
Bristol-Myers Squibb Co. [NYSE: BMY] closed the trading session at $52.34. The company report on March 15, 2024 at 6:27 PM that FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of
Bristol-Myers Squibb Co. [NYSE: BMY] closed the trading session at $53.79. The stocks have a year to date performance of 4.83 percent and weekly performance of 5.70 percent. The stock has been moved at -10.31 percent over the last six months. The stock has performed
Bristol-Myers Squibb Co. [NYSE: BMY] stock went on an upward path that rose over 0.06% on Monday, amounting to a one-week price increase of more than 0.79%. The company report on March 1, 2024 at 4:16 PM that Bristol Myers Squibb Announces Dividend. Bristol Myers
© 2024, Powered by Smart TechOne
